275 related articles for article (PubMed ID: 20724190)
1. [Which modality for prostate brachytherapy?].
Bossi A
Cancer Radiother; 2010 Oct; 14(6-7):488-92. PubMed ID: 20724190
[TBL] [Abstract][Full Text] [Related]
2. [Permanent implant prostate cancer brachytherapy: 2013 state-of-the art].
Cosset JM; Hannoun-Lévi JM; Peiffert D; Delannes M; Pommier P; Pierrat N; Nickers P; Thomas L; Chauveinc L
Cancer Radiother; 2013 Apr; 17(2):111-7. PubMed ID: 23478488
[TBL] [Abstract][Full Text] [Related]
3. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
4. Does brachytherapy have a role in the treatment of prostate cancer?
Grimm PD; Blasko JC; Ragde H; Sylvester J; Clarke D
Hematol Oncol Clin North Am; 1996 Jun; 10(3):653-73. PubMed ID: 8773503
[TBL] [Abstract][Full Text] [Related]
5. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
Nickers P; Thissen B; Jansen N; Deneufbourg JM
Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365
[TBL] [Abstract][Full Text] [Related]
6. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
[TBL] [Abstract][Full Text] [Related]
7. [Prostate cancer brachytherapy].
Pommier P; Guérif S; Peiffert D; Créhange G; Hannoun-Lévi JM; de Crevoisier R
Cancer Radiother; 2016 Sep; 20 Suppl():S210-5. PubMed ID: 27523412
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER).
Valle LF; Lehrer EJ; Markovic D; Elashoff D; Levin-Epstein R; Karnes RJ; Reiter RE; Rettig M; Calais J; Nickols NG; Dess RT; Spratt DE; Steinberg ML; Nguyen PL; Davis BJ; Zaorsky NG; Kishan AU
Eur Urol; 2021 Sep; 80(3):280-292. PubMed ID: 33309278
[TBL] [Abstract][Full Text] [Related]
10. The role of brachytherapy in the definitive management of prostate cancer.
Crook J
Cancer Radiother; 2011 Jun; 15(3):230-7. PubMed ID: 21514199
[TBL] [Abstract][Full Text] [Related]
11. High dose rate brachytherapy in the treatment of prostate cancer.
Vicini F; Vargas C; Gustafson G; Edmundson G; Martinez A
World J Urol; 2003 Sep; 21(4):220-8. PubMed ID: 12905008
[TBL] [Abstract][Full Text] [Related]
12. Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer.
Tharp M; Hardacre M; Bennett R; Jones WT; Stuhldreher D; Vaught J
Brachytherapy; 2008; 7(3):231-6. PubMed ID: 18579446
[TBL] [Abstract][Full Text] [Related]
13. Brachytherapy: current status and future strategies -- can high dose rate replace low dose rate and external beam radiotherapy?
Morton GC; Hoskin PJ
Clin Oncol (R Coll Radiol); 2013 Aug; 25(8):474-82. PubMed ID: 23727431
[TBL] [Abstract][Full Text] [Related]
14. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
15. Dosimetric and radiobiological comparison of volumetric modulated arc therapy, high-dose rate brachytherapy, and low-dose rate permanent seeds implant for localized prostate cancer.
Yang R; Zhao N; Liao A; Wang H; Qu A
Med Dosim; 2016; 41(3):236-41. PubMed ID: 27400663
[TBL] [Abstract][Full Text] [Related]
16. [Brachytherapy for prostate carcinoma].
Yorozu A
Nihon Igaku Hoshasen Gakkai Zasshi; 2005 Apr; 65(2):87-91. PubMed ID: 15920966
[TBL] [Abstract][Full Text] [Related]
17. Loose seeds versus stranded seeds in I-125 prostate brachytherapy: differences in clinical outcome.
Hinnen KA; Moerland MA; Battermann JJ; van Roermund JG; Monninkhof EM; Jürgenliemk-Schulz IM; van Vulpen M
Radiother Oncol; 2010 Jul; 96(1):30-3. PubMed ID: 20215039
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of dosimetry between high-dose-rate and permanent prostate implant brachytherapies in patients with prostate adenocarcinoma.
Wang Y; Sankreacha R; Al-Hebshi A; Loblaw A; Morton G
Brachytherapy; 2006; 5(4):251-5. PubMed ID: 17118319
[TBL] [Abstract][Full Text] [Related]
19. [Brachytherapy for prostate cancer: high dose rate or low-dose rate?].
Cosset JM; Haie-Meder C
Cancer Radiother; 2005 Dec; 9(8):610-9. PubMed ID: 16226473
[TBL] [Abstract][Full Text] [Related]
20. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
